Gossamer Bio

Gossamer Bio

  • Founded: 2017
  • Location: San Diego, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Pulmonary arterial hypertension
  • Drug types: CVV
  • Lead product: Seralutinib
  • Product link: https://www.gossamerbio.com/pipeline/pipeline-overview/
  • Funding: $212M stock Jul 2023; $120M stock Jul 2022; $317M IPO Feb 2019; $230M B Jul 2018; $100M A Jan 2018



job board

Short description:

Small Molecules

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Gossamer Bio is developing therapeutics in immunology, inflammation and oncology. Gossamer Bio’s main strategy is in-licensing of drugs. Through the use of small molecule libraries, Gossamer discovers, develops and acquires drugs that have therapeutic value for diseases with high unmet need. Gossamer tailors in vitro assays to test their drug targets and uses a variety of biochemical techniques and reporter assays. Promising hits are then further investigated in tumor models before entering clinical trials. Gossamer has an ongoing Phase I clinical trial for Primary CNS Lymphoma with multiple preclinical programs in development.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com